SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kfdkfd who wrote (4696)7/2/1998 9:57:00 AM
From: scaram(o)uche  Read Replies (2) of 6136
 
Interesting data. Sounds decent, about what I was expecting. Again, I don't believe that competitive inhibition of co-receptors is going to wash, so I see the beta chemokines as just another marker ass'd with the successful induction of an immune response. I would love to be wrong. Note that I differentiate between "the successful induction of an immune response" and the induction of protective immunity.

"randomized, double-blind"

I would have included a table, with proliferative and MIP-1 data, in the release..... data in the same format as if it had been submitted for publication in a peer-reviewed journal.

Everyone will have their own spin, but, for me, 18/21 and 12/18 are the same numbers. Nonetheless, you can see where IMNR/AGPH will go with this......... meaningful endpoints, given a constructive relationship with FDA, may be easier to come by than some might believe.

So, what are the liars and cheats saying this morning?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext